A study on CHARTwatch reveals its effectiveness in predicting patient deterioration, leading to reduced non-palliative care mortality in general medicine units.
Dermavant maps out atopic dermatitis filing after positive Phase III data – Pharmaceutical Technology
Share this article Vtama gained FDA approval in 2022 to treat plaque psoriasis and generated $28m for the fiscal year ending 31 March 2023. Credit: